Your browser doesn't support javascript.
loading
Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
Nishino, Mizuki; Giobbie-Hurder, Anita; Manos, Michael P; Bailey, Nancy; Buchbinder, Elizabeth I; Ott, Patrick A; Ramaiya, Nikhil H; Hodi, F Stephen.
Afiliação
  • Nishino M; Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts. Mizuki_Nishino@dfci.harvard.edu.
  • Giobbie-Hurder A; Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Manos MP; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
  • Bailey N; Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
  • Buchbinder EI; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
  • Ott PA; Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
  • Ramaiya NH; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
  • Hodi FS; Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Clin Cancer Res ; 23(16): 4671-4679, 2017 Aug 15.
Article em En | MEDLINE | ID: mdl-28592629

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Biomarcadores Tumorais / Anticorpos Monoclonais Humanizados / Melanoma Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Biomarcadores Tumorais / Anticorpos Monoclonais Humanizados / Melanoma Idioma: En Ano de publicação: 2017 Tipo de documento: Article